Get Your Personalized Supplement StackSupplement Stack Quiz

Raw Pancreas Concentrate

Also known as: Raw Pancreas Concentrate, Pancreatic enzyme supplements, Pancreatic extracts, Pancreatic Enzyme Replacement Therapy (PERT)

Overview

Raw Pancreas Concentrate refers to extracts derived from animal pancreas tissue, primarily porcine or bovine, containing essential digestive enzymes such as lipase, amylase, and protease. These enzymes are crucial for breaking down fats, carbohydrates, and proteins in the digestive tract. The concentrate is primarily used as Pancreatic Enzyme Replacement Therapy (PERT) to treat exocrine pancreatic insufficiency (EPI), a condition where the pancreas fails to produce sufficient digestive enzymes. EPI commonly arises from chronic pancreatitis, cystic fibrosis, or pancreatic surgery, leading to malabsorption and nutrient deficiencies. PERT aims to supplement these deficient enzymes, thereby improving digestion and nutrient absorption. The research supporting the efficacy of pancreatic enzyme supplements in treating malabsorption in EPI is extensive and of high quality, including numerous randomized controlled trials and meta-analyses. However, it's important to note that while effective for malabsorption, PERT has not shown significant benefit for pain relief in chronic pancreatitis.

Benefits

Pancreatic Enzyme Replacement Therapy (PERT) offers significant benefits primarily for individuals with exocrine pancreatic insufficiency (EPI). The most robust evidence supports its ability to significantly improve fat absorption and reduce steatorrhea (fatty stools), as consistently demonstrated by improvements in the coefficient of fat absorption (CFA) and other markers in clinical trials and meta-analyses. This leads to improved overall nutrient absorption and a reduction in malabsorption symptoms like diarrhea and weight loss. Patients with chronic pancreatitis, those who have undergone pancreatic surgery, or individuals with cystic fibrosis are the primary beneficiaries, experiencing enhanced digestion and nutrient uptake. Meta-analyses indicate statistically significant and clinically meaningful improvements in fat absorption compared to placebo. While highly effective for malabsorption, PERT does not provide significant benefits for abdominal pain relief in chronic pancreatitis patients. Benefits are typically observed during the period of supplementation, often requiring long-term use for chronic conditions.

How it works

Pancreatic Enzyme Replacement Therapy (PERT) functions by directly supplementing the digestive enzymes that are deficient in individuals with exocrine pancreatic insufficiency (EPI). The key enzymes in the concentrate—lipase, amylase, and protease—are delivered to the small intestine. Once there, they directly facilitate the breakdown of dietary fats (by lipase), carbohydrates (by amylase), and proteins (by protease). This process compensates for the body's insufficient endogenous enzyme production, enabling proper digestion and absorption of macronutrients. The enzymes act locally within the gastrointestinal tract and are not absorbed systemically. Many formulations are enteric-coated to protect the enzymes from degradation by stomach acid, ensuring their activity in the small intestine where digestion primarily occurs.

Side effects

Pancreatic Enzyme Replacement Therapy (PERT) is generally considered safe and well-tolerated when used at recommended doses for the treatment of exocrine pancreatic insufficiency (EPI). Common side effects, occurring in over 5% of users, are typically mild gastrointestinal symptoms such as abdominal pain, flatulence, diarrhea, or constipation. These symptoms can sometimes be difficult to distinguish from those related to the underlying disease itself. Uncommon side effects, affecting 1-5% of users, include rare allergic reactions, though these are not frequent. A rare but serious side effect, occurring in less than 1% of users, is fibrosing colonopathy, which has been reported primarily in cystic fibrosis patients receiving very high doses of enzymes. There are no major documented drug interactions, but the activity of the enzymes can be influenced by acid suppression therapy. PERT is contraindicated in individuals with hypersensitivity to porcine or bovine proteins. Special considerations apply to pediatric and elderly patients, who may require dose adjustments, and close monitoring is advised for cystic fibrosis patients due to the increased risk of fibrosing colonopathy at high doses.

Dosage

The optimal dosage of Pancreatic Enzyme Replacement Therapy (PERT) varies depending on the specific product, the severity of exocrine pancreatic insufficiency (EPI), and individual patient needs. The FDA generally recommends doses sufficient to normalize fat absorption, typically ranging from 25,000 to 80,000 USP lipase units per meal. A common starting point is around 40,000–50,000 USP units of lipase per meal, adjusted based on symptom control and fat absorption test results. The maximum safe dose is generally considered to be up to 10,000 lipase units/kg/day; exceeding this limit, particularly in cystic fibrosis patients, increases the risk of fibrosing colonopathy. PERT should always be taken with meals or snacks to ensure the enzymes are present in the small intestine when food arrives. Enteric-coated formulations are preferred as they protect the enzymes from degradation by gastric acid, allowing them to reach the small intestine intact. Acid suppression therapy, such as proton pump inhibitors, may enhance enzyme activity by further reducing gastric acid levels. No specific cofactors are required, but adequate dietary fat intake is necessary for the enzymes to be utilized effectively.

FAQs

Is Raw Pancreas Concentrate effective for pain relief in chronic pancreatitis?

No, multiple meta-analyses have consistently shown that pancreatic enzyme replacement therapy does not significantly alleviate abdominal pain in patients with chronic pancreatitis.

Is it safe for long-term use?

Yes, when appropriately dosed for exocrine pancreatic insufficiency, pancreatic enzyme replacement therapy is generally safe for long-term use with minimal side effects.

When should it be taken?

It should be taken with meals or snacks to ensure the enzymes are present in the digestive tract when food is consumed, maximizing their effectiveness.

How soon do benefits appear?

Improvements in fat absorption and a reduction in malabsorption symptoms can typically be observed within days to weeks of starting pancreatic enzyme replacement therapy.

Is it suitable for all causes of EPI?

Yes, pancreatic enzyme replacement therapy is suitable for various causes of exocrine pancreatic insufficiency, including chronic pancreatitis, cystic fibrosis, and post-surgical conditions.

Research Sources

https://www.oncotarget.com/article/21659/text/ – This meta-analysis of 7 RCTs found that PERT improved fat absorption and nutritional markers in patients with chronic pancreatitis or post-pancreatic surgery, with no significant safety concerns. However, it concluded that PERT offered no benefit for pain relief, highlighting heterogeneity in disease etiology and treatment regimens as a limitation.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4904687/ – This meta-analysis of 2 crossover RCTs, though of moderate quality due to small sample size, consistently found no significant difference in abdominal pain or analgesic use with enzyme supplementation compared to placebo in patients with chronic pancreatitis, reinforcing the lack of pain relief benefit.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3462488/ – This high-quality systematic review confirmed the efficacy of pancreatic enzymes in improving fat absorption and reducing malabsorption symptoms across multiple RCTs. It also highlighted the ongoing need for more rigorous randomized controlled trials to further refine understanding of PERT.
https://deepblue.lib.umich.edu/bitstream/handle/2027.42/71842/j.1365-2036.2009.04157.x.pdf?sequence=1 – This high-quality systematic review concluded that enzyme supplements effectively improve steatorrhea and fat malabsorption. It also pointed out a lack of comprehensive data on the long-term potency and quality control of various enzyme formulations, noting differences in dosing and formulations across studies.